1031. Effect of On-Site ID Specialist Led, Antimicrobial Stewardship Pharmacist Driven Program on Provider Acceptance, Antimicrobial Utilization and Clostridioides Infection Rates In a Community Hospital / Rural Regional Referral Center

Daniel Brailita, MD[1]; Justin Lane, PharmD[1]; [1]Mary Lanning HealthCare, Hastings, Nebraska,

Session: 131. Antibiotic Stewardship: Interventions
Friday, October 4, 2019: 12:15 PM

Background. Antibiotic Stewardship (ASP) standards for hospitals became effective January 1, 2017. Core Elements implementation guidelines have been challenging for rural hospitals usually lacking on-site expertise. Our 170-bed Community Hospital / rural referral center has dedicated resources for on-site ASP. Our team includes on-site Infectious Disease (ID) Specialist and dedicated ASP pharmacist. Over first 2 years, our model shows very high provider acceptance, improvement in antimicrobial use pattern and reduction in the number of Clostridioides difficile infections (CDI).

Methods. The ASP Pharmacist conducted a daily review of ASP targets. He met with on-site ID Physician 3 days weekly to discuss interventions and review complex cases. The ASP team - ID Medical Director, ASP Pharmacist, Microbiologist, Invention Preventionist and Hospitalist met monthly to discuss outcomes and facility-wide interventions.

ASP audit included: positive cultures, patients on multiple or broad-spectrum antimicrobials, patients receiving dual nephrotoxic drugs, carbapenems, fluoroquinolones, candidates for IV to PO conversion

The audit results were communicated in-person to attending physician and documented in electronic medical record.

Results. ASP team recommendations were accepted in 94% of cases

*ID consult was recommended in 4.*69% and was accepted 100%.

Top 20 IV antimicrobial use decreased by 10%. Fluoroquinolones (29%) and carbapenems (28%) showed highest decrease. Cephalosporins showed small increase.

*Hospital-acquired CDI rate decreased from 0.*83 cases/ 1000 patient-days (PD) pre-ASP to 0.53 cases/ 1000 PD post-ASP. General CDI diagnosis decreased from 3.21 cases/1000 PD pre-ASAP to 2.23 cases/ 1000 PD post-ASP

Conclusion. An on-site, ID Specialist reviewed and dedicated ASP Pharmacist driven program at a rural referral center/ Community Hospital significantly improved antibiotic use and decreased Clostridium Difficile Infections in the first 2 years. Direct feedback of ASP review to providers resulted in an excellent acceptance rate. On-site ID and ASP Pharmacist collaboration is logistically difficult to achieve but expanding our model to rural referral centers should be considered. More research is needed to determine the cost-effectiveness of onsite, dual led programs.

Difference in Antibiotic Utilization after ASP

MDR Pathogens + C. diff by Year

Disclosures. **All authors:** No reported disclosures.

1032. Impact of an Antimicrobial Stewardship Team-Led Initiative – Assessment of Therapy Appropriateness at Patient Discharge

Loveta Eningan. Epie, PharmD[1]; Caroline Timothy, PharmD[1]; Rachid Douglas-Louis, PharmD[1]; Chi Onwumbiko, PharmD; BCPS[1]; Gita K. Shah, MD[1]; [1]University of Maryland Prince George's Hospital Center, Cheverly, Maryland,

Session: 131. Antibiotic Stewardship: Interventions
Friday, October 4, 2019: 12:15 PM

Background. Current focus and emphasis on managed care have encouraged the practice of discharging patients admitted for infections as soon as possible which in-turn has increased the likelihood of patients being discharged on antimicrobials once the acute infection is under control. Many programs have demonstrated success of antimicrobial stewardship (AMS) initiatives but there is little in the published literature surrounding transitional care AMS.

Methods. Patients admitted to University of Maryland Prince George's Hospital who were to be discharged on antimicrobials within 24 hours were identified during multidisciplinary patient rounds over a 2-phase period (each 3 weeks long). Rounds were attended by the AMS team composed of Post-Graduate Year 1 pharmacy residents and/or the AMS pharmacist and/or the AMS physician. Both the choice of antimicrobial and total treatment days including post-discharge days were evaluated and interventions were made based on adherence to current published guidelines. If antimicrobial selection or treatment duration appeared to be inconsistent with guidelines, the case was discussed with the prescriber and agreed-upon changes made prior to the patient's discharge. Accepted and denied recommendations were documented. Patients were also educated on indications, directions and side effects of their antimicrobials.

Results. The AMS team evaluated patients for selected antimicrobial drug and duration of outpatient treatment over the 2-phase period with 20 patients in phase 1 and 26 patients in phase 2. Interventions needed to be made for 100% of patients in phase 1 but only for 50% of patients in phase 2. Duration of treatment was the only intervention which needed to be made with 85% of the interventions in phase 1 accepted and 85% in phase 2. The most common indications for treatment are represented in Figure 1.

*The average decrease in treatment duration for phase 1 and 2 was 3.*6 days and 2.8 days respectively.

Conclusion. These findings suggest that discharge AMS initiatives can decrease patients' overall antimicrobial exposure and potential adverse events, educate providers on treatment guidelines especially of common disease states, increase overall provider compliance with evidence-based literature, and ascertain the appropriateness of therapy choices.

Figure 1. Most Common Indications for Treatment

Disclosures. **All authors:** No reported disclosures.

1033. Effectiveness of a Physician-Driven Automated Antibiotic Time Out in the Setting of Gram-negative Bacteremia

Sana Mohayya, PharmD, MHS[1]; Navaneeth Narayanan, PharmD, MPH[2]; Daniel Cimilluca, MS[1]; Parth Vaidya, PharmD Candidate[2]; Alexander Malanowski, MD Candidate [3]; Tanaya Bhowmick, MD[3]; [1]Robert Wood Johnson University Hospital, New Brunswick, New Jersey; [2]Rutgers University, Ernest Mario School of Pharmacy, New Brunswick, New Jersey; [3]Rutgers Robert Wood Johnson Medical School, New Brunswick, New Jersey,

Session: 131. Antibiotic Stewardship: Interventions
Friday, October 4, 2019: 12:15 PM

Background. In an effort to minimize complications associated with over-utilization of antibiotics, many antimicrobial stewardship programs have incorporated an antibiotic time out (ATO). Despite the increasing adoption of the ATO, limited data are available to support its effectiveness. This study was designed to assess the impact of an automated ATO integrated into the electronic medical record (EMR) on the rate of antibiotic modification in patients receiving broad-spectrum antibiotic(s) for Gram-negative bacteremia (GNB).

Methods. This was a single-center retrospective cohort study of inpatients from January 2017 to June 2018 conducted at a large academic medical center. ATO was implemented on October 31, 2017. Adult patients with GNB who received at least 72

hours of a systemic antibiotic were included. Patients with neutropenia or polymicrobial infections were excluded. The primary outcome was the proportion of patients who received a modification of therapy within 24 hours of final culture results. Secondary outcomes included modification at any point in therapy, time to modification of therapy, time to de-escalation, and days of therapy of broad-spectrum antibiotics.

Results. There was a total of 88 patients who met inclusion criteria, 37 patients pre-ATO and 51 patients post-ATO. The primary outcome of modification of therapy within 24 hours of final culture results was not significantly different for patients in the pre-ATO and post-ATO groups (19% vs. 20%, P = 0.94, respectively). The secondary outcome of modification of therapy at any point in therapy was not significantly different between the two groups (62% vs. 66%, P = 0.67). Of the 47 patients who received a modification of therapy, the mean time to modification was significantly shorter in the post-ATO group (52.8 hours vs. 45.26 hours, P < 0.05,). All other secondary outcomes were not significantly different between study groups.

Conclusion. The ATO alert was not associated with a higher rate of antibiotic modification within 24 hours of culture results in patients with GNB, although there was a significant reduction in the time to antibiotic modification. Further efforts are needed to improve the time to modification and optimize antibiotic prescribing practices.

Disclosures. All authors: No reported disclosures.

1034. Automating Assessments of Vancomycin Appropriateness

Haley K. Holmer, MPH[1]; Caitlin M. McCracken, MA[2];
Gregory B. Tallman, PharmD[3]; Sara J. Gore, MD[1]; Timothy Shan, BS[4];
Diana Yu, PharmD, MS[5]; David T. Bearden, PharmD, FIDP[6];
Jessina C. McGregor, PhD, FSHEA[7]; [1]Oregon Health and Science University, Portland, Oregon; [2]Oregon State University/ Oregon Health Science University, Portland, Oregon; [3]Pacific University School of Pharmacy, Hillsboro, Oregon; [4]Oregon State University College of Pharmacy, Portland, Oregon; [5]Oregon Health and Science University/Doernbecher Children's Hospital, Portland, Oregon; [6]Oregon State University/Oregon Health and Sciences University, Portland, Oregon; [7]Oregon State University/Oregon Health and Science University, Portland, Oregon,

Session: 131. Antibiotic Stewardship: Interventions
Friday, October 4, 2019: 12:15 PM

Background. Assessing appropriateness of hospital antibiotic use is typically a labor-intensive task for antimicrobial stewardship teams and relies heavily on clinician judgement rather than a systematic process. Vancomycin is a frequently used agent that is a common stewardship target. We developed an algorithm to automatically classify the appropriateness of vancomycin days of therapy (DOTs) based upon electronic health record data.

Methods. We constructed a retrospective cohort of Oregon Health and Science University (OHSU) Hospital and Doernbecher Children's Hospital patients admitted August 1, 2017 to July 31, 2018 receiving vancomycin. Data were collected on demographic, encounter, pharmacy, microbiology, and surgery data. An electronic algorithm was applied to classify vancomycin DOTs as appropriate, inappropriate, or indeterminate. Inappropriate use was defined as any case in which there was an opportunity for de-escalation as identified using microbiology data, ICD-10 codes, and procedure codes.

Results. We included 4,231 encounters; 493 (12%) were pediatric patients. Our algorithm automatically classified 59%, 3%, and 38% of encounters as having either appropriate, inappropriate, or indeterminate DOTs, respectively. Forty-four percent of all encounters received no more than a 24-hour course of vancomycin and were considered appropriate empiric therapy; half of these were attributed to surgical prophylaxis. Nine percent of all encounters had vancomycin administered within 3 days of a blood, sputum or tissue culture in which either a methicillin-resistant *Staphylococcus* species or an ampicillin-resistant, vancomycin-susceptible *Enterococcus* species was isolated and were classified as appropriate. Six percent of all encounters had cultures in which only Gram-negatives, fungi, or yeast were isolated and were therefore considered appropriate in the empiric period (≤48 hours) but inappropriate thereafter.

Conclusion. Automated assessments of antibiotic appropriateness could facilitate more informed antimicrobial stewardship initiatives and serve as a valuable stewardship metric. Characterization of indeterminate vancomycin use may inform increased automated classification. Further effort is needed to validate these assessments.

Disclosures. All authors: No reported disclosures.

1035. Implementation of an Antimicrobial Stewardship Program-Led, Multifactorial Pneumonia Diagnosis and Treatment Bundle

Jefferson L. Cua, PharmD[1]; Ryan L. Crass, PharmD[2]; Vince Marshall[1];
Mohammad Ateya, PharmD, MS[2]; Jerod Nagel, PharmD[2];
Gregory Eschenauer, PharmD, BCPS (AQ-ID)[1]; Tejal N. Gandhi, MD[2];
Keith S. Kaye, MD, MPH[3]; Lindsay A. Petty, MD[2]; Carol Chenoweth, MD, MS[1];
Ji Baang, MD, FACP[1]; Alison Lew, PharmD[1];
Twisha S. Patel, PharmD, BCPS, BCIDP[1]; [1]Michigan Medicine, Ann Arbor, Michigan; [2]University of Michigan, Northville, Michigan; [3]University of Michigan Medical School, Ann Arbor, Michigan,

Session: 131. Antibiotic Stewardship: Interventions
Friday, October 4, 2019: 12:15 PM

Background. Pneumonia remains a leading cause of hospitalization and accounts for significant antibiotic use. This study aims to evaluate the impact of bundled antimicrobial stewardship program (ASP) interventions, including procalcitonin and surveillance cultures, on broad-spectrum antimicrobial use in patients with suspected pneumonia.

Methods. This is a pre-post, quasi-experimental study conducted at Michigan Medicine. During the intervention period, an ASP member reviewed adult patients admitted to 3-floor medical services with antibiotics initiated for suspected pneumonia. The ASP member (1) recommended the use of procalcitonin when clinically appropriate, (2) used institutional guidelines to guide empiric antibiotic selection based on risk for drug-resistant pathogens, and (3) ordered a methicillin-resistant *Staphylococcus aureus* (MRSA) surveillance culture in patients receiving empiric anti-MRSA therapy. The primary endpoint was anti-MRSA and anti-pseudomonal (PSA) antibiotic use measured as days of therapy (DOT) per 1000 days-present on the services of interest. Antibiotic use and clinical data were extracted from an electronic database. Pneumonia diagnosis codes were used to identify the study population.

Results. A total of 549 patients were included: 310 in the pre-intervention (December 1/2017 - 3/31/2018) and 239 in the intervention (December 1/2018 - 3/31/2019) periods. Baseline demographics were similar between groups (Table 1). Less than 15% of patients had a microbiological diagnosis via respiratory culture in both study periods (Table 2). Respiratory cultures were ordered less commonly in the intervention period; however, the rate of culture positivity was higher (28% vs. 48%, P < 0.01). Process measures improved in the intervention period with an increase in the proportion of patients with MRSA surveillance cultures (13% vs. 39%, P < 0.01) and procalcitonin monitoring (77% vs. 83%, P = 0.07). Compared with the pre-intervention period, anti-MRSA antibiotic use decreased from 172 to 158 DOT per 1000 days-present (Δ -8%) and the use of anti-PSA antibiotics decreased from 348 to 316 DOT per 1000 days present (Δ -9%).

Conclusion. The implementation of an ASP-led pneumonia bundle led to reductions in anti-MRSA and anti-PSA antibiotic use.

Table 1: Baseline Demographics

Variable	PRE-INTERVENTION (N=310)	INTERVENTION (N=239)	P-value
Age (median, IQR)	66 (55-78)	66 (54-76)	0.58
Male n (%)	159 (51)	131 (55)	0.44
Race n (%)			
Caucasian	247 (80)	172 (72)	0.04
Other or unknown	63 (20)	67 (28)	0.04
Ethnicity n (%)			
Non-Hispanic or unknown	301 (97)	233 (97)	>0.99
Hispanic	9 (3)	6 (3)	>0.99
Body Mass Index (median, IQR)	26.7 (22.3-32.4)	27.1 (22.8-31.8)	0.87
Charlson Comorbidity Index (mean±SD)	4.56 ± 3.98	4.44 ± 3.97	0.72

Table 2: Respiratory Culture and Diagnostic Characteristics

Variable	PRE-INTERVENTION (N=310)	INTERVENTION (N=239)	P-value
No Microbiological Diagnosis n (%)	275 (89)	205 (86)	0.36
Negative Respiratory Cultures n (%)	88 (32)	37 (18)	<0.01
No Cultures Ordered n (%)	187 (68)	168 (82)	<0.01
Microbiological Diagnosis n (%)	35 (11)	34 (14)	0.36
Positive Respiratory Cultures (of those with cultures ordered) n (%)	35/123 (28)	34/71 (48)	<0.01
MRSA Surveillance Culture Ordered n (%)	41 (13)	93 (39)	<0.01
Positive MRSA Screen n (%)	2 (5)	3 (3)	0.64
Procalcitonin Ordered n (%)	238 (77)	199 (83)	0.07

Disclosures. All authors: No reported disclosures.

1036. Clinical impact of an antibiotic time out initiative at an academic medical center

Amy P. Taylor, PharmD[1]; Kelci E. Coe, MPH[2]; Kurt Stevenson, MD, MPH[3];
Lynn Wardlow, PharmD, MBA, BCPS, BCIDP[1];
Zeinab El Boghdadly, MBBCh[4]; Erica E. Reed, PharmD, BCPS-AQ ID[1]; [1]The Ohio State University Wexner Medical Center, Columbus, Ohio; [2]Ohio State University Wexner Medical Center, Columbus, Ohio; [3]The Ohio State University College of